BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave Therapeutics’ assets

BioN­Tech has reached a re­search and op­tion agree­ment with Bio­theus for two an­ti­body can­di­dates.

Bio­theus an­nounced the deal Wednes­day. It will grant BioN­Tech ex­clu­sive world­wide op­tions for a pre­clin­i­cal bis­pe­cif­ic and a clin­i­cal-stage mon­o­clon­al an­ti­body for undis­closed can­cer tar­gets in ex­change for an up­front pay­ment. If BioN­Tech choos­es to li­cense the pre­clin­i­cal can­di­date, Bio­theus will get mile­stone pay­ments and roy­al­ties. The fi­nan­cial specifics were not dis­closed.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN